Generic Medicine Info
Indications and Dosage
Benign prostatic hyperplasia
Adult: As conventional tab: 2.5 mg tid. Max: 10 mg daily. As extended-release tab: 10 mg once daily. 1st dose should be given at bedtime.
Elderly: As conventional tab: Initially, 2.5 mg bid, adjust according to response. Max: 10 mg daily. As extended-release tab: Initially, 5 mg daily, increase to 10 mg daily if necessary. 1st dose should be given at bedtime.

Acute urinary retention associated with benign prostatic hyperplasia
Elderly: As extended-release tab: 10 mg once daily for 2-3 days during catheterisation, and 1 day after removal. Max: 4 days.
Renal Impairment
Benign prostatic hyperplasia:
As conventional tab: Initially, 2.5 mg bid, adjust according to response. As extended-release tab: Mild to moderate: 5 mg once daily, adjust according to response. Severe (CrCl <30 mL/min): Contraindicated.

Acute urinary retention associated with benign prostatic hyperplasia:
Elderly: Severe (CrCl <30 mL/min): Contraindicated.
Hepatic Impairment
Benign prostatic hyperplasia:
As conventional tab: Mild to moderate: Initially, 2.5 mg once daily, may increase to bid according to response. As extended-release tab: Severe (Child-Pugh class C): Contraindicated.

Acute urinary retention associated with benign prostatic hyperplasia:
Elderly: Severe (Child-Pugh class C): Contraindicated.
Should be taken with food.
extended-release: Should be taken with food. Take immediately after the same meal each day. Swallow whole, do not chew/crush.
History of orthostatic hypotension. Severe hepatic and renal impairment. Concomitant use with other α1-receptor blockers and potent CYP3A4 inhibitors.
Special Precautions
Patient with acute cardiac failure, history of tachyarrhythmia or certain CV disease (e.g. myocardial ischaemia), QT prolongation (congenital or acquired), or taking medications that prolong QT interval. Patient undergoing cataract surgery. Mild to moderate renal and hepatic impairment. Not intended for the treatment of hypertension. Not intended for use in women and children. Elderly.
Adverse Reactions
Significant: Angina, CNS depression, intraoperative floppy iris syndrome (cataract surgery patients), orthostatic hypotension, syncope, risk of cerebral ischaemic disorders. Rarely, priapism.
Cardiac disorders: Tachycardia.
Eye disorders: Visual disturbances.
Gastrointestinal disorders: Nausea, diarrhoea, dry mouth, abdominal pain, dyspepsia.
General disorders and admin site conditions: Asthenia, malaise, oedema, chest pain.
Nervous system disorders: Dizziness, vertigo, headache.
Respiratory, thoracic and mediastinal disorders: Rhinitis.
Skin and subcutaneous tissue disorders: Rash, pruritus.
Vascular disorders: Flushing.
Patient Counseling Information
This drug may cause dizziness or weakness, if affected, do not drive or operate machinery.
Monitoring Parameters
Rule out prostatic carcinoma before initiation of therapy (many symptoms of BPH and prostate cancer are similar). Monitor blood pressure (regularly, especially at the beginning of therapy), urine flow, and prostate-specific antigen (PSA).
Symptom: Hypotension. Management: Maintain the patient in a supine position to restore blood pressure and normalise the heart rate. IV fluids and/or vasopressors may also be needed.
Drug Interactions
May enhance the hypotensive effect of antihypertensive agents, nitrates (e.g nitroglycerin, isosorbide dinitrate,) and phosphodiesterase-5 inhibitors (e.g. sildenafil, tadalafil). Administration with general anaesthesia may result in blood pressure instability.
Potentially Fatal: Enhanced hypotensive effect with other α1-blockers (e.g. tamsulosin). Increased serum concentration with potent CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, ritonavir, clarithromycin, telithromycin, nefazodone, nelfinavir).
Food Interaction
Food increases the extent of absorption.
Description: Alfuzosin, a quinazoline derivative that selectively blocks α1-receptors in the lower urinary tract which causes smooth muscle relaxation in the prostate and bladder neck, resulting in the improvement of urine flow and reduction of symptoms in benign prostatic hyperplasia (BPH).
Absorption: Readily absorbed from the gastrointestinal tract. Food increases absorption. Bioavailability: 49% following a meal. Time to peak plasma concentration: 8 hours following a meal.
Distribution: Volume of distribution: 3.2 L/kg. Plasma protein binding: 82-90%.
Metabolism: Extensively metabolised in the liver by CYP3A4 isoenzymes via oxidation, O-demethylation, and N-dealkylation into inactive metabolites.
Excretion: Mainly via faeces (69%); urine (24%; 11% as unchanged drug). Elimination half-life: 10 hours.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 2092, Alfuzosin. Accessed Mar. 29, 2022.

Store below 30°C. Protect from light and moisture.
MIMS Class
Drugs for Bladder & Prostate Disorders
ATC Classification
G04CA01 - alfuzosin ; Belongs to the class of alpha-adrenoreceptor antagonists. Used in the treatment of benign prostatic hypertrophy.
Anon. Alfuzosin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 10/02/2022.

Buckingham R (ed). Alfuzosin Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 10/02/2022.

Joint Formulary Committee. Alfuzosin Hydrochloride. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 10/02/2022.

Preston CL (ed). Alfuzosin Drug Interactions. Stockley’s Drug Interactions [online]. London. Pharmaceutical Press. Accessed 10/02/2022.

Taurazil SR 5 mg Tablets (Generics [UK] Limited t/a Mylan). MHRA. Accessed 10/02/2022.

Uroxatral (Concordia Pharmaceuticals Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 10/02/2022.

Xatral 10 mg Prolonged Release Tablets (Aventis Pharma Limited). MHRA. Accessed 17/02/2022.

Xatral 2.5 mg Film Coated Tablet (Aventis Pharma Limited). MHRA. Accessed 10/02/2022.

Xatral XL 10 mg (Sanofi Winthrop Industrie). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. Accessed 10/02/2022.

Zochek 10 mg Prolonged-Release Tablets (Milpharm Limited). MHRA. Accessed 10/02/2022.

Disclaimer: This information is independently developed by MIMS based on Alfuzosin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
  • Xatral XL
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in